<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00216073</url>
  </required_header>
  <id_info>
    <org_study_id>HOG BRE03-61</org_study_id>
    <nct_id>NCT00216073</nct_id>
  </id_info>
  <brief_title>Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Trial of Capecitabine, Oxaliplatin and Trastuzumab (CAPOX-T) in Patients With HER-2 Positive Metastatic Breast Cancer: Hoosier Oncology Group BRE03-61</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walther Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In vitro data suggest synergy between oxaliplatin and 5-FU. The combination of oxaliplatin&#xD;
      with 5-fluorouracil produced objective response rates ranging from 27-34% in two studies of&#xD;
      patients with prior chemotherapy. Capecitabine was designed as an orally administered, tumor&#xD;
      selective fluoropyrimidine, preferentially converted to 5-FU at the tumor site by the higher&#xD;
      levels of pyrimidine nucleoside phosphorylase (PyNPase) in tumor tissues compared to normal&#xD;
      tissues. The end result is higher concentrations of 5-fluorouracil in tumor relative to&#xD;
      surrounding normal tissue. Trastuzumab is synergistic in vitro with multiple chemotherapeutic&#xD;
      agents including the platinum compounds. Studies have shown the efficacy of trastuzumab&#xD;
      combined with chemotherapy in patients with HER2 overexpressing metastatic breast cancer.&#xD;
      This trial will investigate the activity of capecitabine and oxaliplatin administered with&#xD;
      trastuzumab (CAPOX-T) in patients with HER2 overexpressing in patients with advanced disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.&#xD;
&#xD;
        -  CAPOX-T (21 day cycle):Capecitabine 825 mg/m2 orally twice daily Days 1-14Oxaliplatin&#xD;
           100 mg/m2 intravenously Day 1&#xD;
&#xD;
        -  Trastuzumab : 6 mg/kg intravenously Day 1.8mg/kg loading dose should be given in cycle 1&#xD;
           for patients without previous trastuzumab therapy only.&#xD;
&#xD;
      Patients may continue combination therapy until progression or toxicity intervenes. Patients&#xD;
      who discontinue either or both cytotoxic agents due to toxicity may, at the investigators&#xD;
      discretion, continue therapy with the remaining agents on study until progressive disease&#xD;
&#xD;
      ECOG performance status 0 or 1&#xD;
&#xD;
      Hematopoietic:·&#xD;
&#xD;
        -  ANC &gt; 1,200/mm3·&#xD;
&#xD;
        -  Platelets &gt; 100,000/mm3&#xD;
&#xD;
      Hepatic:·&#xD;
&#xD;
        -  Total bilirubin &lt; 1.5 x ULN·&#xD;
&#xD;
        -  AST &lt; 2 x ULN (up to 5 x ULN in patients with known liver involvement)&#xD;
&#xD;
      Renal:·&#xD;
&#xD;
        -  Serum creatinine &lt; 1.5 x ULN and estimated creatinine clearance &gt;50ml/min as calculated&#xD;
           with Cockroft-Gault equation&#xD;
&#xD;
      Cardiovascular:·&#xD;
&#xD;
        -  No clinically significant cardiac disease (e.g. congestive heart failure, symptomatic&#xD;
           coronary artery disease and cardiac arrhythmias not well controlled with medication) or&#xD;
           myocardial infarction within the last 12 months.·&#xD;
&#xD;
        -  LVEF &gt; LLN by MUGA or ECHO&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of patient accrual&#xD;
  </why_stopped>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- · To determine the objective response rate (CR+PR) of capecitabine, oxaliplatin and trastuzumab(CAPOX-T) in patients with HER2 positive metastatic breast cancer.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure time to progression</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine rate of clinical benefit response (CR + PR + SD &gt; 6 months)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine toxicity rate of CAPOX-T in this patient population</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore potential correlations between changes in HER2 circulating extracellular domain in the primary tumor with response</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine + Oxaliplatin + trastuzumab. Patients must be HER2 positive.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 825 mg/m2 po bid, days 1-14</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 100 mg/m2 IV, day 1</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab 6mg/kg IV, day 1. 8 mg/kg loading dose given in cycle 1 for patients without previous trastuzumab therapy only.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic or cytologic diagnosis of breast cancer with evidence of (1) unresectable,&#xD;
             locally recurrent, or (2) metastatic disease.·&#xD;
&#xD;
          -  HER2 gene amplification by FISH. HER protein overexpression by immunohistochemistry&#xD;
             will not be sufficient for entry.·&#xD;
&#xD;
          -  At least one measurable lesion as defined by the RECIST.&#xD;
&#xD;
          -  Prior hormonal therapy for metastatic disease is allowed.&#xD;
&#xD;
          -  Maximum of one prior chemotherapy regimen or trastuzumab-containing regimen for&#xD;
             unresectable, locally recurrent or metastatic disease&#xD;
&#xD;
          -  Prior radiation therapy is allowed as long as the irradiated area is not the only&#xD;
             source of measurable disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No prior therapy with capecitabine or oxaliplatin in any setting&#xD;
&#xD;
          -  No prior therapy with other platinum compounds·&#xD;
&#xD;
          -  No other forms of cancer therapy including radiation, chemotherapy and hormonal&#xD;
             therapy within 21 days prior to beginning protocol therapy.·&#xD;
&#xD;
          -  No prior unanticipated severe reaction to fluoropyrimidine therapy, or known&#xD;
             sensitivity to 5-fluorouracil.·&#xD;
&#xD;
          -  No prior fluoropyrimidine therapy for metastatic disease is allowed.&#xD;
&#xD;
          -  Prior adjuvant fluoropyrimidine therapy is allowed if completed &gt; 12 months from study&#xD;
             entry.·&#xD;
&#xD;
          -  No symptomatic brain metastasis. ·&#xD;
&#xD;
          -  No evidence of serious concomitant systemic disorders incompatible with the study ·&#xD;
&#xD;
          -  No peripheral neuropathy ·&#xD;
&#xD;
          -  No major surgery within 28 days prior to beginning protocol therapy.·&#xD;
&#xD;
          -  Negative pregnancy test·&#xD;
&#xD;
          -  No current breastfeeding·&#xD;
&#xD;
          -  No malabsorption syndrome·&#xD;
&#xD;
          -  No evidence of serious concomitant systemic disorders incompatible with the study·&#xD;
&#xD;
          -  Patients must not be treated with any of the following while on protocol therapy or&#xD;
             within 28 days prior to beginning protocol therapy: sorivudine, brivudine, cimetidine,&#xD;
             allopurinol.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathy Miller, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Oncology Group, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical &amp; Surgical Specialists, LLC</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center of Southern Indiana</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkhart Clinic</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Oncology &amp; Hematology, Inc</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Cancer Center (MCGOP)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Regional Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Consultants, P.C.</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Cancer Research Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP&amp;S Clinic</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Hematology/Oncology of S. Michigan</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://hoosieroncologygroup.org/</url>
    <description>Hoosier Oncology Group Home Page</description>
  </link>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>April 29, 2011</last_update_submitted>
  <last_update_submitted_qc>April 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kathy Miller, M.D.</name_title>
    <organization>Hoosier Oncology Group</organization>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

